...
首页> 外文期刊>Heart rhythm: the official journal of the Heart Rhythm Society >Presence of left ventricular contractile reserve predicts midterm response to cardiac resynchronization therapy--results from the LOw dose DObutamine stress-echo test in Cardiac Resynchronization Therapy (LODO-CRT) trial.
【24h】

Presence of left ventricular contractile reserve predicts midterm response to cardiac resynchronization therapy--results from the LOw dose DObutamine stress-echo test in Cardiac Resynchronization Therapy (LODO-CRT) trial.

机译:左心室收缩储备的存在可预测对心脏再同步治疗的中期反应-心脏再同步治疗(LODO-CRT)试验中LOw剂量DObutamine压力回声测试的结果。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Cardiac resynchronization therapy (CRT) is effective in selected patients with heart failure (HF). Nevertheless, the nonresponder rate remains high. The low-dose dobutamine stress-echo (DSE) test detects the presence of left ventricular (LV) contractile reserve (LVCR) in HF patients of any etiology and may be useful in predicting response to resynchronization. OBJECTIVE: The purpose of this study was to present the results of the LODO-CRT trial, which evaluated whether LVCR presence at baseline increases the chances of response to CRT. METHODS: LODO-CRT is a multicenter prospective study that enrolled CRT candidates according to guidelines. LVCR presence was defined as an LV ejection fraction increase >5 units during DSE test. CRT response is assessed at 6-month follow-up as an LV end-systolic volume reduction >/=10%. RESULTS: Two hundred seventy-one patients were enrolled. The DSE test was feasible without complications in 99% of patients. Nine patients died from noncardiac disease, and 31 presented inadequate data. Two hundred thirty-one patients were included in the analysis. Mean patient age was 67 +/- 10 years; 95% were in New York Heart Association class III, and 42% had HF of ischemic etiology. Mean QRS and LV ejection fraction were 147 +/- 25 ms and 27% +/- 6%, respectively. LVCR presence was found in 185 subjects (80%). At follow-up, 170 (74%) patients responded to CRT, 145/185 in the group with LVCR (78%) and 25/46 (54%) in the group without LVCR. Difference in responder proportion to CRT was 24% (P <.001). Reported test sensitivity is 85%. CONCLUSION: The DSE test in CRT candidates is safe and feasible. LVCR presence at baseline increases the chances of response to CRT.
机译:背景:心脏再同步治疗(CRT)对某些心力衰竭(HF)患者有效。但是,无应答率仍然很高。低剂量多巴酚丁胺应激回声(DSE)测试可检测任何病因的HF患者中左心室(LV)收缩储备(LVCR)的存在,可能有助于预测对再同步的反应。目的:本研究的目的是介绍LODO-CRT试验的结果,该试验评估了基线时LVCR的存在是否增加了对CRT反应的机会。方法:LODO-CRT是一项多中心前瞻性研究,根据指南招募了CRT候选人。 LVCR的存在定义为DSE测试期间LV射血分数增加> 5个单位。在6个月的随访中评估CRT反应,因为LV收缩末期容积减少> / = 10%。结果:271例患者入组。 DSE测试在99%的患者中没有并发症是可行的。 9名患者死于非心脏疾病,其中31名患者的数据不足。分析中包括了231位患者。平均患者年龄为67 +/- 10岁; 95%的患者属于纽约心脏协会的III级患者,其中42%的患者患有缺血性心衰。平均QRS和LV射血分数分别为147 +/- 25 ms和27%+/- 6%。 185名受试者(80%)发现存在LVCR。随访时,有170例(74%)患者对CRT有反应,其中LVCR组为145/185(78%),无LVCR组为25/46(54%)。响应者与CRT的比例差异为24%(P <.001)。报告的测试灵敏度为85%。结论:在CRT候选人中进行DSE测试是安全可行的。基线存在LVCR会增加对CRT做出反应的机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号